Comprehensive Accounts of Pharmaceutical Research and Development

Ahmed F. Abdel-Magid received his Bachelor's degree (1969) and Master's degree (1973) from Cairo University and his PhD (1980) from Temple University. After postdoctoral appointments at the University of South Carolina and SmithKline Beckman Pharmaceuticals, he worked at Drexel University as Teaching/Research Associate (1985-1986) then as Adjunct Professor (1986-2006). He joined the Process Chemistry Department at Wyeth Laboratories as Senior Chemist (1986-1987), then moved to the Process Chemistry Group at Johnson & Johnson PRD (1987-2008) as a Senior Scientist and rose through the ranks to Senior Research Fellow. He joined Therachem Research Medilab in 2009 where he holds the title of Executive VP and Chief Scientific Officer. Jaan A. Pesti received his BS degree from Long Island University, Brooklyn, NY in 1976 and his Ph.D. in organic chemistry from Columbia University in 1981. Following postdoctoral research in synthetic organic chemistry at University of California, Berkeley from 1981-1983, he joined the staff of Dupont's Medical Products Division in Wilmington, DE and Deepwater, NJ. He later transitioned to Dupont Merck Pharmaceuticals, Dupont Pharmaceuticals, and joined Bristol-Myers Squibb Pharmaceuticals in 2001. He retired from BMS in 2013 after 30 years of service, but has worked for NAL Pharma, Gelest Inc., and EnginZyme AB since that date. Rajappa Vaidyanathan obtained his Bachelor's degree from Loyola College, Madras, and his Master's from the Indian Institute of Technology, Madras. He completed his Ph.D. in 1998 from the University of California, Irvine. After a post-doctoral appointment at Eli Lilly and Company, he joined the Chemical Process R&D group of Pharmacia Corporation, Kalamazoo, MI, and subsequently Pfizer in Groton, CT. He is currently Group Director and Head of Chemical, Synthetic and Analytical Development at Bristol-Myers Squibb in Bangalore, India.

Preface
1. Discovery and Chemical Development of Suvorexant - A Dual Orexin Antagonist for Sleep Disorder
2. Discovery of Novel Protein Fucosylation Inhibitors and Development of a Manufacturing Process To Prepare Inhibitor 6,6,6-Trifluorofucose
3. Development of Hsp90 Inhibitors for the Treatment of HER-2 Positive Solid Cancers
4. Discovery of the Novel Oxadiazole-Containing 5-Lipoxygenase Activating Protein (FLAP) Inhibitor BI 665915
5. Development of an Efficient Asymmetric Synthesis of the Chiral Quaternary 5-Lipoxygenase Activating Protein Inhibitor
6. The Discovery and Process Chemistry Development of GDC-0084, a Brain Penetrating Inhibitor of PI3K and mTOR
7. Discovery and Development of Doravirine: An Investigational Next Generation Non-Nucleside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV
8. The Discovery of Dacomitinib, a Potent Irreversible EGFR Inhibitor
9. Early and Late Stage Process Development for the Manufacture of Dacomitinib
10. Discovery and Development of the Natural Product Derivative SPI-1865 as a Gamma Secretase Modulator for Alzheimer's Disease: Part I
11. Discovery and Development of the Natural Product Derivative SPI-1865 as a Gamma Secretase Modulator for Alzheimer's Disease
12. Telaprevir: From Drug Discovery to the Manufacture of Drug Substance
Editors' Biographies
Indexes